Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Tide turns against River Esk wave turbines

Montrose Bridge.
Montrose Bridge.

Montrose’s largest employer has been refused permission to install tidal turbines in the River Esk on environmental grounds.

Marine Scotland has turned down a licence application from GlaxoSmithKline to install 15 turbines at the mouth of Montrose Basin.

The regulator said it would not issue a marine licence due to the site being designated as a special protection area, a site of special scientific interest and a special area of conservation.

In a letter explaining the decision to GSK, Marine Scotland said: “The decision is based upon the high sensitivity of the site, the poor state of some of the qualifying species and the difficulty in quantifying the likely significant effects.

“It is considered that you cannot ascertain with certainty that the proposal will not have a significant adverse impact on the environment and the local amenity.”

The pharmaceutical giant planned to deploy Swanturbines devices on either side of Montrose Bridge in the multi-million pound proposal.

Each turbine would have been capable of generating around 0.66 megawatts when the tide flowed in and out of the basin enough to provide around 7% of the power required by the Montrose factory.

A spokesman from GSK said it accepted the decision and was now working with Marine Scotland on an alternative proposal using bladeless turbines.

He said: “Although modelling undertaken on behalf of GSK indicated that the blades of the turbines would not have had an adverse environmental impact, GSK recognises that Montrose Basin is environmentally sensitive and accepts Marine Scotland’s decision.

“GSK is working with Marine Scotland on an alternative proposal which would use bladeless turbines harnessing technology supported by Scottish Enterprise which has been trialled and proven at the EMEC (European Marine Energy Centre) based in the Orkneys.

“The company intends to submit to Marine Scotland an application for a generation licence to deploy and monitor a single turbine in the river close to Montrose Bridge.

“Should Marine Scotland grant the application and the trial proves successful, GSK would seek permission to install a further five turbines.

“The six machines would cost in the region of £5 million and be capable of generating 540 kilowatts of electricity.

“The turbines would be linked direct to the GSK Montrose site, where the green energy would help to reduce both the site’s carbon footprint and operating costs.”

The decision to refuse the application has been welcomed by RSPB Scotland’s marine conservation planner Charles Nathan.

He said: “Whilst GlaxoSmithKline’s vision of sourcing green energy to support their operations is commendable, Marine Scotland has made the right decision not to grant consent for a project sited in a highly environmentally sensitive area, where the potential impact on wildlife was significant.

“RSPB Scotland believes there is a need for greater focus on delivering sustainable offshore renewables but this should be restricted to the least sensitive sites.

“Hopefully, GSK can find a suitable alternative to deliver their own sustainability goals without posing a threat to local marine life.”

GSK is also seeking to install two wind turbines more than 328ft high at its Montrose plant as it seeks to reduce its carbon footprint.

The application was refused by Angus Council but GSK has lodged an appeal.